IBRANCE® IS THE FIRST FDA-APPROVED MEDICATION in its class. IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not a traditional chemotherapy. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see Important Safety Information.
In combination with any aromatase inhibitor, IBRANCE is for postmenopausal women as their first hormonal based therapy.
IBRANCE was studied in a clinical trial of 666 postmenopausal women with ER+/HER2- metastatic breast cancer who had not received prior hormone therapy for their metastatic disease. Patients were split into 2 groups. The first group took IBRANCE and letrozole (an aromatase inhibitor) together, while the second group took letrozole and placebo.
DELAYED DISEASE PROGRESSION
MEDIAN TIME TO DISEASE PROGRESSION
Together, the combination of IBRANCE and letrozole delayed disease progression for a median time of 24.8 months versus 14.5 months for those that received letrozole and placebo. Patients taking IBRANCE with letrozole reduced their risk of disease progression by 42% compared to those taking letrozole and placebo.
This means that IBRANCE plus letrozole was significantly more effective at delaying disease progression versus letrozole and placebo.
This clinical trial is ongoing to measure the total time patients live from the start of treatment (overall survival).
In the same clinical trial, tumor response to treatment was measured. The results showed that in patients taking IBRANCE and letrozole, tumor response was 55%—meaning more than half of these patients saw their tumors shrink in size —compared to 44% who took letrozole and placebo.
TALKING TO YOUR DOCTOR
Find helpful questions to ask your doctor about IBRANCE.
How IBRANCE Works
SLOWING THE PROGRESSION OF METASTATIC BREAST CANCER
IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not a traditional chemotherapy. IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see theto learn more.
Learn How IBRANCE & Hormonal Therapies Work Together
The video below shows how IBRANCE and hormonal therapies bring the power of two therapies together to help delay the progression of a certain type of metastatic breast cancer.
Starting a new treatment can be overwhelming. You—and those who care for you—may have questions, and that’s to be expected. This video can help explain how IBRANCE® (palbociclib) works as a treatment for a certain type of metastatic breast cancer.
Metastatic breast cancer, or mBC, is breast cancer that has spread to other parts of the body, such as the bones, liver, lungs, and brain.
Let’s now take a closer look at the role hormones play in the body as well as how both IBRANCE and hormonal therapy work.
Hormones are substances that act as chemical messengers, traveling through the bloodstream to help perform activities specific to cells and organs.
Estrogen and progesterone are two such hormones that occur naturally in the body. These hormones attach to hormone receptors in order to help promote normal cell growth and function.
Hormone receptors are proteins found within and on the surface of cells, including breast cells. The binding of hormones to the receptors is like flipping an on-switch for the activity and function of the cell.
The binding of hormones like estrogen and/or progesterone to their hormone receptors in cells triggers cell growth by communicating with proteins known as CDK4 and CDK6. These proteins play an important role in cell division.
The breast cancer we are focused on here is known as hormone receptor positive or (HR+), human epidermal growth factor receptor 2-negative or (HER2-) metastatic breast cancer. Or, more simply put, HR+, HER2- mBC.
In HR+, HER2- mBC, the increase of certain proteins, like CDK4 and CDK6, can contribute to the cell being overactive. That overactivity can cause the cell to lose its ability to regulate its growth and division.
This can lead to the production of many cancerous cells that can move to different areas of the body. Blocking the ways in which a cell grows and divides can slow the progression of certain breast cancers, including HR+, HER2- mBC.
This is where IBRANCE can play a role.
IBRANCE is taken in combination with hormonal therapy to help delay the progression of metastatic breast cancer.
IBRANCE works inside the cell to disrupt the activity of the proteins CDK4 and CDK6, which can keep both healthy and cancer cells from dividing.
Hormonal therapy works to block or reduce the binding of hormones with hormone receptors to prevent the cells from growing and dividing.
By working together, IBRANCE and hormonal therapy can help delay the progression of HR+, HER2- metastatic breast cancer.
Talk to your doctor if you have any additional questions about IBRANCE. Information can also be found throughout IBRANCE.com.
While on therapy, be sure to share any side effects you experience with your healthcare team right away.
SERIOUS SIDE EFFECTS
- Low white blood cell counts (neutropenia) are very common when taking IBRANCE (palbociclib) and may cause serious infections that can lead to death. Your healthcare team should check your white blood cell counts before and during treatment.
- If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.
- Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your doctor right away if you have any new or worsening symptoms, including:
- chest pain
- cough with or without mucus
- trouble breathing or shortness of breath
Your doctor may interrupt or stop treatment with IBRANCE completely if your symptoms are severe.
THE MOST COMMON SIDE EFFECTS
- In addition to low white blood cell counts (neutropenia), low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare team right away if you feel dizzy or weak, notice that you bleed or bruise more easily, or experience shortness of breath or nosebleeds while on treatment.
- Other most common side effects include infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite.
Not all of the possible side effects are listed here. For more information, talk to your doctor, nurse, or pharmacist.
Brochures To Download
Download our Patient Guide for an overview of IBRANCE.
Download our Caregiver Guide for information specific for caregivers.